TY - JOUR
T1 - Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder
AU - Talkowski, Michael E.
AU - Mullegama, Sureni V.
AU - Rosenfeld, Jill A.
AU - Van Bon, Bregje W.M.
AU - Shen, Yiping
AU - Repnikova, Elena A.
AU - Gastier-Foster, Julie
AU - Thrush, Devon Lamb
AU - Kathiresan, Sekar
AU - Ruderfer, Douglas M.
AU - Chiang, Colby
AU - Hanscom, Carrie
AU - Ernst, Carl
AU - Lindgren, Amelia M.
AU - Morton, Cynthia C.
AU - An, Yu
AU - Astbury, Caroline
AU - Brueton, Louise A.
AU - Lichtenbelt, Klaske D.
AU - Ades, Lesley C.
AU - Fichera, Marco
AU - Romano, Corrado
AU - Innis, Jeffrey W.
AU - Williams, Charles A.
AU - Bartholomew, Dennis
AU - Van Allen, Margot I.
AU - Parikh, Aditi
AU - Zhang, Lilei
AU - Wu, Bai Lin
AU - Pyatt, Robert E.
AU - Schwartz, Stuart
AU - Shaffer, Lisa G.
AU - De Vries, Bert B.A.
AU - Gusella, James F.
AU - Elsea, Sarah H.
N1 - Funding Information:
We are thankful to all of the subjects and families involved in this study. We are grateful for the assistance of Jennifer Defant, Santhosh Girirajan, Stephen Williams, Zalak Shah, and Tracey Oh in the collection of clinical data and in the preparation of this manuscript. We thank Pamela Sklar and the International Schizophrenia Consortium for contributing control data and Nancy J. Van Vranken for patient referral. We are also grateful to Manuel Rivas for assistance with the Syzygy analysis. We thank the Fondation Jérôme Lejeune (S.H.E.) for funding portions of this study, Developmental Genome Anatomy Project(GM061354), HD065286, National “973” project on Population and Health of China (2010CB529601), Science and Technology Council of Shanghai (09JC1402400 and 09ZR1404500), and the Simons Foundation Autism Research Initiative. M.E.T. was supported by a National Institutes of Health National Research Service Award (F32MH087123). The authors would also like to thank the NHLBI GO Exome Sequencing Project and its ongoing studies that produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the Women's Health Initiative Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). Fichera and Romano were supported by a grant from the “5 per mille” program.
PY - 2011/10/7
Y1 - 2011/10/7
N2 - Persons with neurodevelopmental disorders or autism spectrum disorder (ASD) often harbor chromosomal microdeletions, yet the individual genetic contributors within these regions have not been systematically evaluated. We established a consortium of clinical diagnostic and research laboratories to accumulate a large cohort with genetic alterations of chromosomal region 2q23.1 and acquired 65 subjects with microdeletion or translocation. We sequenced translocation breakpoints; aligned microdeletions to determine the critical region; assessed effects on mRNA expression; and examined medical records, photos, and clinical evaluations. We identified a single gene, methyl-CpG-binding domain 5 (MBD5), as the only locus that defined the critical region. Partial or complete deletion of MBD5 was associated with haploinsufficiency of mRNA expression, intellectual disability, epilepsy, and autistic features. Fourteen alterations, including partial deletions of noncoding regions not typically captured or considered pathogenic by current diagnostic screening, disrupted MBD5 alone. Expression profiles and clinical characteristics were largely indistinguishable between MBD5-specific alteration and deletion of the entire 2q23.1 interval. No copy-number alterations of MBD5 were observed in 7878 controls, suggesting MBD5 alterations are highly penetrant. We surveyed MBD5 coding variations among 747 ASD subjects compared to 2043 non-ASD subjects analyzed by whole-exome sequencing and detected an association with a highly conserved methyl-CpG-binding domain missense variant, p.79Gly>Glu (c.236G>A) (p = 0.012). These results suggest that genetic alterations of MBD5 cause features of 2q23.1 microdeletion syndrome and that this epigenetic regulator significantly contributes to ASD risk, warranting further consideration in research and clinical diagnostic screening and highlighting the importance of chromatin remodeling in the etiology of these complex disorders.
AB - Persons with neurodevelopmental disorders or autism spectrum disorder (ASD) often harbor chromosomal microdeletions, yet the individual genetic contributors within these regions have not been systematically evaluated. We established a consortium of clinical diagnostic and research laboratories to accumulate a large cohort with genetic alterations of chromosomal region 2q23.1 and acquired 65 subjects with microdeletion or translocation. We sequenced translocation breakpoints; aligned microdeletions to determine the critical region; assessed effects on mRNA expression; and examined medical records, photos, and clinical evaluations. We identified a single gene, methyl-CpG-binding domain 5 (MBD5), as the only locus that defined the critical region. Partial or complete deletion of MBD5 was associated with haploinsufficiency of mRNA expression, intellectual disability, epilepsy, and autistic features. Fourteen alterations, including partial deletions of noncoding regions not typically captured or considered pathogenic by current diagnostic screening, disrupted MBD5 alone. Expression profiles and clinical characteristics were largely indistinguishable between MBD5-specific alteration and deletion of the entire 2q23.1 interval. No copy-number alterations of MBD5 were observed in 7878 controls, suggesting MBD5 alterations are highly penetrant. We surveyed MBD5 coding variations among 747 ASD subjects compared to 2043 non-ASD subjects analyzed by whole-exome sequencing and detected an association with a highly conserved methyl-CpG-binding domain missense variant, p.79Gly>Glu (c.236G>A) (p = 0.012). These results suggest that genetic alterations of MBD5 cause features of 2q23.1 microdeletion syndrome and that this epigenetic regulator significantly contributes to ASD risk, warranting further consideration in research and clinical diagnostic screening and highlighting the importance of chromatin remodeling in the etiology of these complex disorders.
UR - http://www.scopus.com/inward/record.url?scp=80053931230&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2011.09.011
DO - 10.1016/j.ajhg.2011.09.011
M3 - Article
C2 - 21981781
AN - SCOPUS:80053931230
SN - 0002-9297
VL - 89
SP - 551
EP - 563
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 4
ER -